Business
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
Short Term Tranche Warrants Potentially Raise $10.4 Million within 12 months of ClosingSAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced the pricing of its underwritten public offering of 10,519,631 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof), (ii) one 6 month warrant
About this update from Calidi Biotherapeutics, Inc.
[{"type":"image","alt":"Calidi Biotherapeutics, Inc","displaySize":"","headline":null,"caption":"Calidi Biotherapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TVVsA9n31LT1YQqkVdlDAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1","width":300,"height":93}},"lazy":false},{"type":"text","content":"Short Term Tranche Warrants Potentially Raise $10.4 Million within 12 months of Closing","length":87,"tagName":"p"},{"type":"text","content":"SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced the pricing of its underwritten public offering of 10,519,631 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof), (ii) one 6 month warrant to purchase one share of common stock, (iii) one 12 month warrant to purchase one share of common stock and (iv) one five year warrant to purchase one share of common stock (collectively, the “Warrants”) .","length":619,"tagName":"p"},{"type":"text","content":"Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager for the offering.","length":100,"tagName":"p"},{"type":"text","content":"Each unit is being sold to the public at a price of $0.50 per unit and each pre-funded unit is being sold to the public at the public offering price of each unit less the $0.001 per share nominal exercise price for each pre-funded warrant. The gross proceeds to the Company from this offering are expected to be approximately $5.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses.","length":434,"tagName":"p"},{"type":"text","content":"The Company has granted the underwriter a 45-day option to purchase up to an additional 1,575,000 shares of common stock and/or warrants to purchase up to 1,575,000 shares of common stock for each series of warrants described above (or up to an aggregate of 4,725,000 shares of common stock), or any combination thereof, solely to cover over-allotments, if any, a...